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Glioblastoma multiformePancytopenia is a rare side effect of levetiracetam (LEV) that is associated with severe morbidity that requires
hospitalization. Here, we report a patient with a right temporoparietal tumor who underwent a temporal crani-
otomywith resection of themass andwas started on LEV for seizure prophylaxis per the neurosurgery local pro-
tocol. The patient developed LEV-induced pancytopenia, which was successfully managed by discontinuation of
this medication. Our report aims to increase awareness of this rare cause of pancytopenia among clinicians.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Levetiracetam is a pyrrolidone derivative that is thought to exert its
antiepileptic effects via adherence to the synaptic vesicle protein SV2A
and modulation of neurotransmitter release. Levetiracetam is a water-
soluble drug that is excreted by the kidneys with a half-life of 6–8 h.
Thus, patients with renal impairment achieve serum levels that are typ-
ical for treating epilepsy with lower doses based on their creatinine
clearance. Levetiracetamwas found to be effective as adjunctive therapy
in patients with refractory focal epilepsy, lowering seizure frequency by
at least 50% in 40% of that population. In addition, it is used as adjunctive
therapy for myoclonic epilepsy and primary generalized tonic–clonic
seizures. There are no signiﬁcant drug interactions between LEV and
other medications, such as warfarin, digoxin, oral contraceptives,
probenecid, and other antiseizure medications. However, it should be
used with caution in alcoholic patients because it may increase the
risks of sedation and seizures [1,6].
Levetiracetam causes several adverse neurological effects that in-
clude headache, somnolence, asthenia, dizziness, irritability, and
behavioral changes. In addition, it can cause hematological side effects
such as mild thrombocytopenia, leukopenia, and anemia that may not
necessitate its discontinuation [1]. Pancytopenia is a very rare adverse
effect of LEV. There are three case reports in the medical literature
discussing the association between LEV and pancytopenia. The
pathogenesis behind this relationship is unclear. Our report aims atogy, Epilepsy Center George
W; #9-405, Washington DC,
6; 216 280 9433 (Mobile).
. This is an open access article underincreasing the awareness of this rare cause of pancytopenia that neces-
sitates discontinuation of this drug.2. Case report
A brain MRI of a 79-year-old woman with a medical history of hy-
pertension, type II diabetes, and stroke revealed a right temporoparietal
mass. She was started on dexamethasone prior to surgery because of
extensive vasogenic edema. She underwent a temporal craniotomy
with resection of the mass and was started on LEV for seizure prophy-
laxis per the neurosurgery protocol, though this is not an approved
use of LEV. The pathology showed glioblastomamultiforme. Postopera-
tively, her blood counts remained stable. Her medication regimen in-
cluded LEV, dexamethasone, pantoprazole, and enoxaparin for deep
venous thrombosis prophylaxis. She was noted to have an episode of
melena and anemia on the ﬁfth postoperative day, which required
transfusion with two units of red blood cells with an appropriate re-
sponse. No acute gastroenterological intervention was deemed nec-
essary. The patient was also noted to have thrombocytopenia and
leukopenia. Her blood smear did not show any signs of hemolysis
as shown in Fig. 1. Thrombotic thrombocytopenic purpura, dissemi-
nated intravascular coagulation, and heparin-induced thrombocyto-
penia were ruled out. Pantoprazole and enoxaparin were
discontinued without any improvement in cell counts. The patient
received a total of ﬁve units of platelets because of platelet counts
of less than 100,000. Levetiracetam was replaced subsequently by
lacosamide (LCM) on the tenth postoperative day, and dexamethasone
was continued without change. Within 24 h of discontinuing LEV, thethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Blood smear showing lack of schistocytes and immature cell lines. Findings on blood
smear correlate with absence of disseminated intravascular coagulation and thrombotic
thrombocytopenic purpura and are suggestive of bone marrow suppression.
Fig. 3. Graph depicting relationship between white blood cell count and number of days
postoperatively (POD). LEV was started on postoperative day 0 and was discontinued on
postoperative day 10. Development of leukopenia was witnessed with start of LEV, and
improvement in leukopenia was observed with discontinuation of the medication.
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increase in white blood cells and hemoglobin was seen within ﬁve
days as shown in Figs. 2, 3, and 4.
3. Discussion
Hematological side effects of LEV are extremely rare and have been
limited to isolated cases of mild thrombocytopenia, leukopenia, or ane-
mia [5–7]. The present case demonstrates development of pancytopenia
induced by LEVwith resolution after discontinuation of thismedication.
On literature review, three other cases of pancytopenia with the use of
LEV have been reported. The ﬁrst case is that of a 76-year-old woman
who had a seizure in the setting of an ischemic stroke and developed
pancytopenia two days after initiation of LEV [3]. The second case is a
65-year-oldwomanwho received LEV after undergoing surgical remov-
al of a meningioma and developed pancytopenia 9 days after initiation
of treatment, with bone marrow aspiration showing medullary hypo-
plasia [4]. The third case is a 16-year-old young woman with history
of Lafora disease who experienced pancytopenia 4 days after initiation
of LEV treatment and recovered with discontinuation of themedication
[2]. The fact that these patients presented with different diagnoses sug-
gests that LEV, rather than a complication of the underlying disease, was
the cause of pancytopenia. In addition, no one concomitant medication
was common to all reported cases, and none of these reports studied
HLA typing as a potential predisposing factor.
In the present case, all other causes of hematologic disturbance such
as thrombotic thrombocytopenic purpura, disseminated intravascular
coagulation, and heparin-induced thrombocytopenia were ruled out.Fig. 2. Graph depicting relationship between red blood cell count and hemoglobin and
number of days postoperatively (POD). LEV was started on postoperative day 0 and was
discontinued on postoperative day 10. The patient experienced an acute bleed requiring
transfusion of 2 units of RBC on POD 5, followed by a steady decline in Hgb and RBC. Im-
provement in anemia was observed with discontinuation of the medication.Other medications such as enoxaparin and pantoprazole with potential
hematologic side effects were discontinued without improvement in
blood counts. The patient's hemolysis proﬁle and blood smear did not
reveal any signs of hemolysis. Therefore, we hypothesized that LEV
induced pancytopenia in our patients through bone marrow
suppression.
4. Conclusion
Clinicians should be aware that LEV can cause severe pancytopenia,
and consider discontinuation of LEV in patients who develop pancyto-
penia with negative hemolysis proﬁle. Further studies should evaluate
the mechanisms by which LEV induces bone marrow suppression and
possibly ﬁnd a blood test for proper diagnosis.
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